Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 07 - 11 save search
Exelixis to Approach FDA with Mixed Renal Cell Carcinoma Data
Published: 2022-07-11 (Crawled : 21:00) - biospace.com/
EXEL 4 | $22.83 0.57% 0.57% 1.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
fda renal cell carcinoma
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme PanelMolecular Diagnostic Test for Early Detection of Lyme Disease
Published: 2022-07-11 (Crawled : 14:00) - biospace.com/
TTOO | $3.05 2.69% 2.62% 84K
|
Health Technology
|
| O: 12.63%
H: 3.76%
C: -10.33%
fda designation device disease test diagnostic
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
Published: 2022-07-11 (Crawled : 13:20) - biospace.com/
AEMD | $1.45 -1.96% 8.1K
|
Health Technology
|
| O: -1.94%
H: 4.95%
C: 0.0%
covid-19 fda approval study
FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment
Published: 2022-07-11 (Crawled : 13:20) - biospace.com/
LPCN | $5.355 -10.46% 37K
|
Health Technology
|
| O: 6.06%
H: 0.0%
C: -4.06%
treatment fda
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
Published: 2022-07-11 (Crawled : 12:20) - biospace.com/
CANF | $2.21 6.76% -0.45% 13K
|
Health Technology
|
| O: 0.0%
H: 14.44%
C: 12.22%
treatment fda piclidenoson ema psoriasis
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
Published: 2022-07-11 (Crawled : 12:20) - globenewswire.com
TTOO | $3.05 2.69% 2.62% 84K
|
Health Technology
|
| O: 12.63%
H: 3.76%
C: -10.33%
fda designation device
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
Published: 2022-07-11 (Crawled : 12:00) - globenewswire.com
ITRM | $1.465 -6.69% -7.17% 170K
|
Health Technology
|
| O: 25.0%
H: 55.93%
C: 12.33%
fda therapeutics agreement
Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill
Published: 2022-07-11 (Crawled : 11:00) - biospace.com/
PRGO A | $29.96 -0.56% 0.0% 1.4M
|
Health Technology
|
| O: 0.85%
H: 3.06%
C: 1.3%
fda pharma application control
Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients
Published: 2022-07-11 (Crawled : 09:00) - biospace.com/
NYXH | $9.45 6.18% 5.82% 66K
|
n/a
|
| O: 12.13%
H: 4.24%
C: -1.78%
genio fda approval study
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.